Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)

v3.19.3
STOCKHOLDERS' EQUITY (DEFICIT) (Tables)
6 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Schedule of outstanding warrants

The following is a summary of the Company’s outstanding warrants at September 30, 2019:

 

Warrants     Exercise     Expiration     Intrinsic Value at  
Outstanding     Price ($)     Date     September 30, 2019  
  1 (1)     1,171,875.00       April 26, 2021     $  
  3 (2)     195,412.50       September 12, 2022        
  32 (3)     12,187.50       May 24, 2023        
  36                     $  

 

  (1) Warrants issued in connection with the sale of convertible notes. The warrants were exercisable on the grant date (April 26, 2016) and remain exercisable until April 26, 2021.
  (2) Warrants issued in connection with the Initial Tranche of the funding from Vantage. The warrants were exercisable on the grant date (September 12, 2017) and remain exercisable until September 12, 2022.
  (3) Warrants issued in connection with the Severance Agreement with Richard N. Azar II. The warrants were exercisable on the grant date (May 25, 2018) and remain exercisable until May 24, 2023.